Self-emulsifying drug delivery systems (SEDDS) have been used to solubilize poorly water-soluble drugs to improve exposure in high-dose pharmacokinetic (PK) and toxicokinetic (TK) studies. However, the absorbable dose is often limited by drug solubility in the lipidic SEDDS vehicle. This study focuses on increasing solubility and drug loading of ionizable drugs in SEDDS vehicles using lipophilic counterions to prepare lipophilic salts of drugs. SEDDS formulations of two lipophilic salts-atazanavir-2-naphthalene sulfonic acid (ATV-2-NSA) and atazanavir-dioctyl sulfosuccinic acid (ATV-Doc)-were characterized and their performance compared to atazanavir (ATV) free base formulated as an aqueous crystalline suspension, an organic solution, and a SEDDS suspension, using in vitro, in vivo, and in silico methods. ATV-2-NSA exhibited $6-fold increased solubility in a SEDDS vehicle, allowing emulsion dosing at 12 mg/mL. In rat PK studies at 60 mg/kg, the ATV-2-NSA SEDDS emulsion had comparable exposure to the free-base solution, but with less variability, and had better exposure at high dose than aqueous suspensions of ATV free base. Trends in dose-dependent exposure for various formulations were consistent with GastroPlus TM modeling. Results suggest use of lipophilic salts is a valuable approach for delivering poorly soluble compounds at high doses in Discovery.
Introduction
Driven by the complexity of pharmacological targets, pharmaceutical pipelines are increasingly filled with poorly watersoluble compounds. The factors contributing to this trend include the addition of lipophilic residues to increase ligand-receptor affinity, the broadening of the chemical space using combinatorial chemistry, and the use of high-throughput screening [1, 2] . Highly potent compounds may be discovered through these means, but their poor water solubility can lead to numerous challenges during development-particularly, reduced systemic exposure after oral administration [3] .
Poorly water-soluble molecules present a particular formulation challenge for high-dose studies-both in Discovery and in later stages of development. In Discovery, high-dose studies are invaluable in aiding early identification of toxicity-the leading cause of attrition at all stages of drug development [4] . High doses are also required in pharmacokinetic (PK) studies, especially toxicokinetic (TK) studies, where high-exposure multiples are required to evaluate safety margins over the entire range of efficacious exposure.
Advances in the pharmaceutical sciences have produced numerous approaches to address the challenges presented by poorly water-soluble compounds, which are designated Class II and IV compounds in the Biopharmaceutics Classification System (BCS). These strategies include reducing particle size to increase the surface area and dissolution rate [5] ; solubilization in cosolvents [6] ; complexation [7, 8] ; formulation as solid amorphous dispersions [9] ; formation of salt forms [10] ; and the use of lipidic systems for lipophilic drugs [11] . Each approach has its limitations. For example, reducing particle size has little impact on solubilitylimited exposure, solubilization in cosolvents is restricted to a limited range of pharmaceutically acceptable excipients, and the binding constant of inclusion complexes is often insufficient to solubilize the required dose using acceptable amounts of complexing agents. Solid amorphous dispersions offer improved solubilization, but are not as facile to prepare as liquid lipid-based formulations.
The formation of salt forms and the use of lipidic systems for lipophilic drugs offers particular promise in addressing the need for stable, high-dose formulations. Salt formation using small, often inorganic, counterions is a well-established technique to increase the dissolution rate and kinetic solubility of drug compounds [12] [13] [14] [15] [16] [17] . Although these high-energy salts can increase the oral bioavailability of poorly soluble ionizable compounds, this approach can be limited by the disproportionation of salt to the free-drug form, with concomitant crystallization to a low-energy crystal. To prevent this, many investigators have proposed modifying the physiochemical properties of poorly water-soluble drug compounds using lipophilic counterions to form lipophilic salts (sometimes referred to as ''ionic liquids") as an alternative to high-energy salt forms, to enable more effective formulation, delivery, and oral absorption [18] [19] [20] [21] [22] [23] .
Lipid-based formulations have numerous desirable features; they are easy to manufacture and can increase stability, enhance absorption, and improve bioavailability [24] . However, the drug solubility in the lipid often limits the maximum dose deliverable using lipid vehicles. It would be advantageous to extend the applicability of lipid formulations to a broader range of compounds, particularly those with lower log P values (e.g., between 2 and 5) and higher melting-point (T m ) values, such as atazanavir, the model drug used in the work described here.
Lipophilic ion-drug pairs can markedly increase solubility in lipidic phases through a combination of two mechanisms: (1) the lipophilicity of the counterion, which can help pull the drug into a lipid phase; and (2) the reduced crystalline forces (and T m ) of the ion-drug pair, which tends to increase solubility in all solvents. The increased lipid solubility of such salts can facilitate development of stable, high-concentration formulations for high-dose pharmacokinetic or toxicokinetic studies, which in turn can result in higher exposures than those achievable with formulations of other salts or free forms of the drug. Reports have detailed the use of lipophilic counterions to form ion-drug pairs that enable higher drug loadings in solid lipid nanoparticles [25] [26] [27] or into oil-in-water emulsion droplets [28] . More recently, Shadid et al. showed a 2.5-fold increase in oral exposure in rats for sulfasalazine when formulated as an ''ionic liquid" [23] . In addition, Sahbaz et al. demonstrated improved oral exposure in rats for three poorly soluble compounds by formulating them with a variety of lipophilic counterions [22] .
The purpose of the work described here is to demonstrate the feasibility of using lipophilic ion-drug pairs (i.e., salts) in lipid vehicles to enable dosing of poorly water-soluble drugs at high concentrations for preclinical studies. Demonstrating that this promising approach is suitable for high-dose testing, particularly in a Discovery setting, would be valuable, since solubilizing high doses of such drugs is difficult in lipid vehicles using free-acid/free-base drug forms or typical high-energy salt forms.
This study describes the use of lipophilic counterions to prepare lipophilic salt forms of a weakly basic drug-atazanavir (ATV)-to increase drug solubility in a self-emulsifying drug-delivery system (SEDDS) vehicle (above that achievable with the free base and typical inorganic salts of the drug) to increase the deliverable dose, enabling high-dose testing. The synthesis, characterization, formulation development, and in vivo PK profiles of the lipophilic salts atazanavir 2-naphthalene sulfonic acid (ATV-2-NSA) and atazanavir-dioctyl sulfosuccinic (''docusate") acid (ATV-Doc) are described. ATV, which is an antiretroviral drug of the protease inhibitor class [29] [30] [31] [32] , was chosen as a model compound due to its low aqueous solubility ($1.5 lg/mL at pH 6.5) and weakly basic pKa ($4.6). 2-naphthalene sulfonic acid (2-NSA) and dioctyl sulfosuccinic acid (Doc) were chosen as counteracids because of their low pKa values [16] , which result in complete protonation of ATV at intestinal pH, as well as for their pharmaceutical precedence [33, 34] and low toxicity [35] . The SEDDS formulation chosen is typical of a Type II formulation in the lipid formulation classification system (LFCS) described in the literature [36, 37] , but was not optimized for ATV.
Materials and methods

Materials
All reagents and solvents were used as received. ATV was obtained from Bristol-Myers Squibb (New York, New York). 
Methods
Preparation of amorphous ATV free base
Amorphous ATV free base was prepared by spray-drying ATV free base from solution on a custom mini spray dryer designed and built at Bend Research, a division of Capsugel [9] . ATV free base was dissolved in methanol at a concentration of 18 mg/mL and spray-dried at an inlet temperature of 65°C and a nitrogen flow rate of 30 standard liters per min.
Preparation of ATV salts
The ATV salts were prepared quantitatively by stoichiometric addition of strong acids to the ATV free base. The 2-NSA and Doc salts were both isolated in the amorphous form. The 2-NSA salt was also separately isolated as crystalline material. The Doc salt was not easily isolated in the crystalline form, so only the amorphous form was characterized.
Preparation of ATV-2-NSA salt
Amorphous ATV-2-NSA salt was prepared by dissolving 2.27 g of ATV free base in 50 mL of methanol. To this solution, 0.74 g of 2-NSA was added with stirring. The resulting solution was rotoevaporated to dryness and placed under vacuum overnight, yielding an off-white solid.
Crystalline ATV-2-NSA salt was prepared by dissolving 1.22 g of ATV free base in 50 mL of methanol. To this solution, 0.42 g of 2-NSA in 10 mL of methanol was added with stirring. The resulting solution was rotoevaporated to dryness. The solid was dissolved in 30 mL of methyl acetate with mild heating, and then cooled to ambient temperature. The mixture was allowed to sit at ambient temperature while being monitored for the appearance of crystals over time. After 3 days, there being no further apparent increase in precipitate, the white crystalline solid was isolated by filtration, rinsed with 50 mL of methyl acetate, and then rinsed with 30 mL of diethyl ether and dried.
Preparation of ATV-Doc salt
Amorphous ATV-Doc salt was prepared by converting docusate sodium to docusic acid followed by reaction with ATV free base. Docusate sodium (1.380 g) was dissolved in 25 mL of anhydrous THF. Methanolic HCl (2.005 g, 1.25 M) was added with stirring to produce a white precipitate of sodium chloride. The mixture was chilled to 0°C and then filtered through a 0.45-lm filter, resulting in a clear solution of docusic acid. The docusic acid was added with stirring to a solution of ATV free base, 2.04 g in 75 mL of methanol, giving a clear solution that was rotoevaporated to dryness and further dried under vacuum to give an amorphous solid.
Unsuccessful attempts were made to isolate crystalline ATVDoc salt. ATV-DOC (0.445 g) was dissolved in methyl acetate (1.096 g) and placed in a freezer overnight. As this resulted in no precipitation of crystals, diethyl ether (10.34 g), was then added to the solution, which remained clear at room temperature. This solution was then placed in a freezer overnight, with solids being observed the next day. The sample was kept in the freezer for a total of 4 days. Solids were harvested and analyzed by PXRD to confirm the amorphous nature of the solid.
Measurement of ATV content of salts
Solid samples of ATV-2-NSA and ATV-Doc salts were dissolved in methanol in triplicate, and the concentration of the active compound (i.e. ATV free base equivalent) was measured using the HPLC method described below.
Preparation of SEDDS vehicle
The SEDDS vehicle was prepared by combining Miglyol 812 (35% w/w), Capmul MCM C10 (15% w/w), and Tween 80 (50% w/ w) and heating to 80°C, followed by stirring and cooling to room temperature.
Measurement of solubility
To determine the solubility of ATV free base, ATV-2-NSA, and ATV-Doc in the SEDDS vehicle, SEDDS vehicles containing excess solids of each drug form were stirred for six days at ambient temperature. Aliquots (900 lL) were taken from each suspension in duplicate and centrifuged using a Beckman Optima TM Max ultracentrifuge (Beckman-Coulter Inc., Danvers, Massachusetts) at 470,000g for 20 min at 23°C. The supernatants were sampled and diluted 1:10 in methanol and analyzed by HPLC. The amorphous solubility of ATV in PBS at pH 6.5 was determined by adding a concentrated DMSO solution (5 mg/mL) of ATV free base into PBS, and using ultraviolet (UV) probes to measure the maximum concentration reached before light scattering occurred due to phase separation of drug from solution [38] [39] [40] [41] .
Evaluation of SEDDS and SEDDS emulsion stability
To determine the physical stability of SEDDS formulations, solutions of ATV free base, ATV-2-NSA, and ATV-Doc were prepared in the SEDDS vehicles at up to 100 mg/mL and observed visually for precipitation. The clear SEDDS formulations were diluted 1:4 by weight with 0.01 N HCl to prepare SEDDS emulsions. The resulting emulsions were then placed onto a nutating mixer at 24 rpm at room temperature. Aliquots (500 lL) were taken immediately after preparation and at 1-and 2-h time points and transferred to microcentrifuge tubes. The samples were then centrifuged for 1 min at 16,000g. The supernatant was sampled and diluted 1:10 in methanol and analyzed by HPLC. Any precipitate was isolated and characterized by powder X-ray diffraction (PXRD). In addition to the stability of the emulsion with respect to crystallization of the drug, the size and size stability of the emulsion droplet size of SEDDS emulsions were determined by dynamic light scattering (DLS) using a BI-200SM particle size analyzer with a BI-9000AT correlator (Brookhaven Instruments Inc., Holtsville, NY). Measurements were made of SEDDS emulsions at low drug concentration (1-2 mg/mL) immediately after preparation, and after storage at ambient for 24 h, in order to assess the stability of the lipid droplet size in the emulsion.
Measurement of composition by HPLC
The compositions of the isolated ATV salts were determined by measuring the amount of ATV free base equivalent in a given mass of each isolated solid. Drug-containing samples were analyzed by reverse-phase (RP) HPLC using a Hewlett Packard instrument (Series 1100, Hewlett Packard Development Corp., Palo Alto, California) with a C18 column (Agilent Zorbax Ò SB-C18, 3.5 lm, 75 mm Â 4.6 mm) using an injection volume of 10 lL, column temperature of 25°C, and flow rate of 1.5 mL/min with UV detection at 254 nm. ATV had a retention time of approximately 1.8 min using an isocratic method and a mobile phase of 60:40 ACN:0.1% TFA in water.
Evaluation of physical state by PXRD
ATV free base, ATV-2-NSA, and ATV-Doc were analyzed by PXRD using a Bruker D8 Advance X-ray diffractometer (Bruker Corp., Billerica, Massachusetts) with a Lynxeye TM XE positionsensitive detector and Cu K-alpha radiation (1.54 Å). Approximately 10-20 mg of powder was placed in a zero-backgroundholder (ZBH) sample cup containing a single-crystal silicon surface and covered with a polyether ether ketone (PEEK) dome. The sample cup was rotated at 30 rpm in the horizontal plane, while the goniometer was stepped through a 2h angle of 4°to 40°with a 0.04°step size at 1 s/step. The primary beam optics included a Goebel mirror, 1-mm dispersive slit, and a 2.5°soller slit. The diffracted beam optics included a 5.84 mm antiscatter slit and a 2.5°soller slit.
Evaluation of thermal characteristics by modulated differential scanning calorimetry (mDSC)
The glass-transition temperatures (T g ) of the amorphous spraydried ATV free base, ATV-2-NSA, and ATV-Doc isolated by rotoevaporation were determined using a TA Q-1000 mDSC instrument (TA Instruments, New Castle, Delaware). Samples were prepared as 5-mm compacts in hermetic T zero TM pans (TA Instruments) with open lids, and were equilibrated at room temperature at <5% relative humidity (RH) overnight. Samples were sealed and then run in modulated mode from À20°C to 200°C at 2.5°C/min with ±1.5°C/ min modulation. T g values were determined using TA Instrument software and quantified as the half-height of the thermal transition in the reversing heat-flow curve.
Assessment of salt formation by nuclear magnetic resonance (NMR)
ATV free base, ATV-2-NSA, and ATV-Doc were dissolved at 15-40 mg/mL in d 6 DMSO. d 1 H NMR spectra were recorded on a Varian 600-MHz Fourier transform (FT) instrument with 64 scans. Chemical shifts were reported in parts per million (ppm).
Preparation of SEDDS formulations for PK studies
The SEDDS formulations were prepared by first dissolving amorphous ATV free base (at 10 and 30 mg/mL); amorphous ATV-2-NSA (at 10, 30, and 60 mg/mL); and amorphous ATV-Doc (at 10 and 30 mg/mL) separately in the SEDDS vehicle. SEDDS emulsions were then prepared by diluting the SEDDS formulations 1:4 in 0.01 N HCl before administration. The SEDDS formulations were diluted in acidic media instead of in media of higher pH in order to limit the concentration of ATV free base in the aqueous phase, in which it has a propensity to crystallize. The SEDDS formulations were emulsified prior to dosing in order to ensure accurate transfer of the dose, as the high viscosity of the (unemulsified) SEDDS solution can make it difficult to transfer the formulations from the dosing device to the animal during in vivo studies, leading to variability in exposure. Solution formulations of crystalline ATV free base were prepared (at 10 and 30 mg/mL) using 10% v/v DMAC, 40% v/v PEG 400, and 15% v/v Kleptose HPB, and 35% v/v citrate buffer (citric acid monohydrate, pH 4.0, 50 mM). ATV free base was not soluble at 60 mg/mL in this vehicle, so the highest dose was prepared using amorphous ATV free base in 100% PEG 400. ATV free base was also dosed as an aqueous suspension prepared (at 2 and 20 mg/mL, respectively, for 10 and 100 mg/kg doses) in 0.5% w/w Methocel A4 M, 0.1% w/w Tween 80, and 99.4% w/w water.
Animals
Male Sprague-Dawley rats weighing 280 ± 40 g were obtained from the Syngene International Ltd. in-house breeding facility (Bangalore, India). All animal experiments were conducted in the animal research Syngene facility (Bangalore, India), which is registered by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), after approval by the Institutional Animal Ethics Committee (IAEC). The animals were fed with a standard laboratory rodent diet (Tetragon Chemie Pvt. Ltd., Bangalore, India) and housed at room temperature (22°C ± 3°C) and 50% RH ± 20% RH on a 12-h light-dark cycle. All animals were fasted overnight before dosing. Water was provided ad libitum throughout the study.
PK studies
Test Preparation: Cannulas were implanted in the jugular vein of all rats and a recovery period of 24 h was provided after surgery. Cannulated rats (n = 3 per group) were fasted for approximately 16 h before peroral dosing and fed 3 h after dosing. ATV freebase suspension (at 10 and 100 mg/kg); ATV free-base solution (at 10, 30, and 60 mg/kg); ATV free-base SEDDS (at 10 and 30 mg/kg); ATV-2-NSA SEDDS (at 10, 30, and 60 mg/kg); and ATV-Doc SEDDS (at 10 and 30 mg/kg) formulations were administered by oral gavage using a feeding needle (5 mL/kg). Blood samples (150 lL) were collected from the jugular-vein catheter 0.25, 0.5, 1, 3, 5, 7 and 24 h after dosing. The blood sample volume was replaced with an equal volume of 0.9% saline. Blood samples were collected into tubes containing K 2 EDTA (1.33 mM) and were inverted several times to disperse the anticoagulant. They were then kept chilled on ice until centrifugation, which occurred within 30 min of sample collection. Blood was centrifuged at 10,000g for 5 min at 4°C. Plasma was harvested and transferred into tubes, which were then stored at À70°C (±10°C) until the samples were analyzed.
Sample preparation for bioanalysis: An ATV calibration standard was prepared in rat plasma by a serial dilution method for the concentration range of 1.22-5000 nM. Aliquots (25 Quantitation was achieved by MS/MS detection in positive-ion multiple reaction monitoring (MRM) mode using an API 4000 MS instrument (Applied Biosystems, Foster City, California, USA) with an electrospray positive ionization (ESI) source at a capillary voltage of 5.5 kV and a source temperature of 500°C. Quadrupoles Q1 and Q3 were set at unit resolution with a dwell time of 30 ms for each MRM (705.5/335.2). Analytical data were acquired and processed using Analyst Ò software (Version 1.5, Sciex, Framingham, Massachusetts, USA). The accuracy and precision of the ATV calibrations standard was well within the acceptance limit for the bioanalytical method (<±20% at lower limit of quantification [LOQ] and <±15% at other concentrations). PK Data Analysis: The PK parameters for ATV were determined by noncompartmental analysis of plasma concentration-versustime data using Kinetica TM software (Version 5.1, Thermo Fisher Scientific Corporation, Philadelphia, Pennsylvania, USA). The peak concentration (C max ) and time for C max (T max ) were recorded directly from experimental observations. The area under the plasma concentration-time curve (AUC 0-t ) was calculated using mixed log-linear trapezoidal rule up to the last detectable concentration (C last ) and extrapolated to infinity (AUC 0-1 ) by adding C last / kz to AUC 0-t. Estimation of the terminal elimination rate constant (kz) was made using a minimum of three time points with quantifiable concentrations.
PK parameters were expressed as the mean plus or minus the standard deviation (SD). An analysis of variance (ANOVA) was performed to assess differences between more than two groups, followed by a Tukey multiple comparisons test, wherever appropriate. Comparison between two groups was conducted using the two-tailed t-test using GraphPad Prism Ò software (Version 5.02, (GraphPad Software Inc., San Diego, California, USA). A p-value of less than 0.05 was considered statistically significant.
In silico PK modeling
In silico simulations used to predict drug plasma concentrations from an oral dose in a fasted rat animal model were performed using the GastroPlus TM advanced compartmental and transit (ACAT) model (Version 9.0) by Simulations Plus Inc. Clearance and compartment rate constants were obtained for a three-compartment model, by fitting intravenous (IV) bolus PK data (collected inhouse) for 1-and 5-mg/kg doses. Given the extensive cytochrome P450 (CYP) metabolism of ATV [42] [43] [44] , we also fit MichaelisMenton kinetic parameters-V max (the maximum rate achieved by the enzymatic system, at saturating substrate concentration) and k m (the substrate concentration at which the enzymatic reaction rate is half of V max )-for liver metabolism to the IV bolus data. The PK curves for ATV-2-NSA SEDDS and ATV solution at 10, 30, and 60 mg/kg, and the ATV free-base aqueous suspension administered at 100 mg/kg were used in a global optimization routine to fit Michaelis-Menton kinetic terms for CYP metabolism in the gut and efflux transporters in the gut enterocytes [45] . A pattern search method using the Hooke and Jeeves method was used to match predicted AUC 0-t and predicted drug plasma concentration for the average of three sets of in vivo data consisting of the SEDDS and PEG solution formulations dosed at 10, 30, and 60 mg/kg. An overall effective permeability value (P eff ) of 0.45 cm/s was estimated from single-pass perfusion studies of rat intestinal segments [45] . A solubility of 1.5 lg/mL at a pH of 6.5 was used for the crystalline free base, and the measured ''amorphous solubility" of 65 lg/mL at pH 6.5 was used for the SEDDS formulation. We assumed this solubility was maintained when the drug was in the un-ionized state. Drug partitioning from the dispersed SEDDS oil phase is expected to be rapid, and thus was taken to be instantaneous in the model. Additionally, it was assumed that the solubilities of the crystalline and amorphous drug forms followed the Henderson-Hasselbalch relationship [46] .
Results
The purpose of this study was to demonstrate the utility of lipophilic salts to enable dosing of poorly soluble drugs at high concentrations. ATV was used as a model weakly basic drug compound, and 2-NSA and Doc were selected as model lipophilic counterions. The chemical structure and properties of ATV free base, 2-NSA, and Doc are shown in Fig. 1 . The solid salt forms of ATV-2-NSA and ATV-Doc were characterized by PXRD, mDSC, and d 1 H NMR, evaluated for solubility and physical stability in the SEDDS vehicle, and assessed for in vivo performance.
Characterization of the lipophilic salts
Reaction of ATV free base with the two sulfonic acids, 2-NSA and Doc, gave the corresponding salt forms in high yield. The ATV-2-NSA and ATV-Doc salts formed readily, as expected, since the pKa of ATV (4.7) is more than four units higher than the pKa values of the strongly acidic sulfonic acid groups of 2-NSA and Doc. The ATV-2-NSA and ATV-Doc salts were isolated by rotoevaporation followed by drying under high vacuum, producing solids that were characterized by PXRD. As shown in Fig. 2 , diffractograms of the solid powders showed amorphous ''halos" with no evidence of distinct diffraction peaks.
The amorphous nature of ATV-2-NSA and ATV-Doc suggested by PXRD analysis was supported by mDSC data, showing clear T g events in the reversing heat flow of the thermal scans. As shown in Fig. 3 and Table 1 , the T g of amorphous ATV-2-NSA was 15°C higher than that of the amorphous ATV free base, and the T g of ATV-Doc was more than 30°C below that of the amorphous ATV free base. The lower T g of ATV-Doc relative to the free base may be due to the highly flexible nature of the docusate moiety. The docusate sodium itself has a low T g (À13°C) (data not shown). Only the ATV free base showed a recrystallization, at $162°C. The lack of a T m for the 2-NSA salt in Fig. 3 is consistent with the amorphous nature of this sample. The 2-NSA salt sample that was crystallized from methyl acetate did show a T m of 172°C (data not shown).
The thermal data and ATV free base content of the salts is summarized in Table 1 . As the table shows, the measured free base equivalent content of the ATV-2-NSA and ATV-Doc salt samples was consistent with their theoretical values. Table 2 . The spectra were assigned based on the spectrum of 2-phenyl pyridine [47] in conjunction with two-dimensional correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY), and heteronuclear single-quantum correlation (HSAC) spectroscopy of the ATV free base, ATV-2-NSA, and ATV-Doc (data not shown). As shown in the spectra of Fig. 4 and the shift data in Table 2 , for ATV-2-NSA and ATV-Doc, the pyridyl protons (A, B, C, and D) shifted significantly downfield (by up to 0.52 ppm) relative to those of ATV free base. The phenyl protons (E and F), which are further removed from the protonatable pyridyl ring, shifted only slightly upfield and downfield, respectively. The benzyl protons (G, HR, and I), which are far removed from the protonatable pyridyl group, showed essentially no shift for the two salt forms relative to their chemical shift for the free-base form.
The solubility of ATV free base, ATV-2-NSA and ATV-Doc in the SEDDS vehicle was determined by adding excess solids of each drug form to the SEDDS vehicle and stirring for several days to reach equilibrium. For ATV free base and ATV-2-NSA, the crystalline form was used. For ATV-Doc, the amorphous solid was used, since crystalline ATV-Doc could not be isolated. The results are summarized in Table 1 . Crystalline ATV-2-NSA had a 5.7-fold higher solubility than crystalline ATV free base in the SEDDS vehicle. The amorphous solubility ATV-Doc in the SEDDS vehicle was approximately 3.7-fold higher than the crystalline solubility of ATV free base.
Physical stability in SEDDS vehicle and as emulsions
The physical stability of the various drug forms in SEDDS formulations at several concentrations was assessed by dissolving the amorphous forms of ATV free base (at 10, 30, and 60 mg/ mL); ATV-2-NSA (at 30 and 60 mg/mL); and ATV-Doc (at 10, 30, and 60 mg/mL) in the SEDDS vehicle. The resulting supersaturated solutions were monitored for precipitation. As anticipated, the precipitation rate increased as the concentration of drug in the SEDDS vehicle increased. ATV free base at 10 and 30 mg/mL stayed in solution for up to 6 and 1.5 h, respectively, whereas at 60 mg/mL, precipitation was observed within 0.25 to 0.5 h. Due to the rapid precipitation, no further tests were conducted with ATV free base at 60 mg/mL. ATV-Doc had better stability in the SEDDS vehicle. At 10, 30, and 60 mg/mL, ATV-Doc solution formulations did not precipitate for up to 6, 3.5, and 1 h, respectively. Of the three drug forms, ATV-2-NSA had the best stability in the SEDDS vehicle. No precipitation was observed for up to 30 h, even at 60 mg/mL.
To determine if changes in physical form occurred when the salts were added to the SEDDS vehicle, PXRD was used to compare the crystalline precipitates isolated from the ATV-2-NSA and ATVDoc SEDDS formulations to those for two controls: crystalline ATV-2-NSA (prepared by crystallization from methyl acetate) and ATV free base. As the results in Fig. 5 show, the diffraction patterns for crystalline solids obtained from the ATV-2-NSA and ATV-Doc SEDDS vehicle match those of the crystalline ATV-2-NSA and ATV free-base forms, respectively. This confirms that ATV-2-NSA is a more stable salt in the SEDDS vehicle than ATV-Doc, which disproportionates to a larger extent, precipitating as the ATV free base.
SEDDS emulsions were diluted to make dosing easier and to ensure accurate transfer of the dose during in vivo testing. Two potential diluents-0.01 N HCl and water-were tested. A significant improvement in the emulsion stability was observed when the ATV-NSA SEDDS vehicle was diluted with 0.01 N HCl (5% precipitation) versus water (33% precipitation). Based on these results, 1:4 dilution with 0.01 N HCl was used for subsequent tests.
SEDDS emulsion formulations were tested for stability to ensure minimal precipitation of drug occurred between preparation of the emulsion and dosing. Table 3 summarizes the stability results of SEDDS emulsions of different formulations as a function of concentration. In this study, the potency of ATV in the supernatant of the SEDDS emulsion after centrifugation was measured immediately after preparation (i.e., initial), after 1 h, and after 2 h, and the results were compared to the total potency. As the table shows, at 10 mg/mL, the ATV free-base SEDDS emulsion concentration was stable over 2 h, but significant ATV precipitation (77%) was observed at 2 h for the 30 mg/mL ATV free-base SEDDS emulsion. After dilution, the 30 mg/mL ATV-Doc SEDDS emulsion was more stable than the ATV free-base emulsion at the same concentration, but 1:4 dilution of the 60 mg/mL ATV-Doc SEDDS solution with 0.01 N HCl resulted in 82% precipitation of the ATV by 2 h. When diluted similarly, the 30 and 60 mg/mL ATV-2-NSA SEDDS solutions resulted in emulsions that were fairly stable, with only 5% to 15% loss of ATV due to precipitation. Similar dilutions of 100 mg/mL ATV-2-NSA resulted in more than half the drug precipitating from the resulting emulsion within 2 h. The emulsion droplet size for SEDDS emulsions, as determined by effective diameter from DLS, was typically 200-300 nm, and did not change appreciably over the course of 24 h after preparation.
Initial PK studies
SEDDS formulations showing acceptable in vitro stability were selected for in vivo assessment in rats: ATV free base (at 10 and 30 mg/mL), ATV-2-NSA (at 10, 30, and 60 mg/mL), and ATV-Doc (at 10 and 30 mg/mL). Two control formulations-an aqueous suspension containing crystalline ATV free base and an organic solution of ATV free base-were also tested (at 10 and 100 mg/kg, and 10, 30, and 60 mg/kg, respectively for the suspension and solution). The ATV free-base solution was used as a positive control to show the maximum exposure achievable when the dissolved-drug concentration was maximized, whereas the ATV free-base crystalline suspension was used as a second control to show the exposure resulting from the very low dissolved-drug levels supplied by the low-energy crystalline drug form. Exposure increased with increasing dose for all three SEDDS formulations and for the ATV free-base solution formulations. Higherthan-dose-proportional exposure was observed for SEDDS formulations containing ATV free base and ATV-Doc at 10 and 30 mg/ kg. This is shown by the data in Table 4 and Fig. 6 . However, after dose normalization at 10 mg/kg, the difference between the 10 mg/ kg and 30 mg/kg dose groups for these two formulations was not statistically significant, due to high variability observed at 30 mg/ kg and the small number of animals in each group (n = 3). Due to Table 4 PK parameters (mean ± SD) of ATV following oral administration of ATV SEDDS emulsions, ATV free-base crystalline suspensions, and ATV free-base solutions. limited stability of the ATV free-base SEDDS formulation and the ATV-Doc SEDDS formulation at 60 mg/mL (as shown by the data in Table 3 ), neither of these formulations was evaluated at this concentration.
Like the ATV free-base SEDDS and ATV-Doc SEDDS formulations, the ATV-2-NSA SEDDS formulation and ATV free-base solution exhibited higher-than-dose-proportional exposure between 10 mg/kg and 60 mg/kg. The interanimal variability for the ATV-2-NSA SEDDS formulation at 60 mg/kg was substantially lower (a coefficient of variation [CV] of 13% for AUC 0-1 ) than for the ATV free-base solution (a CV of 54% for AUC 0-1 ), as shown by the data in Table 4 and Fig. 6 . Exposure from the ATV free-base crystalline suspension was low at both doses tested, likely due to solubilitylimited absorption.
The dose responses (i.e., exposure) for the ATV-2-NSA SEDDS formulations and the two control formulations are shown in Fig. 7 . Also plotted are the simulated dose responses predicted by GastroPlus TM simulations (note that since the simulated curves for the ATV-2-NSA SEDDS and the ATV free-base solution overlay, only the former is plotted). As shown, the simulated curves for the ATV-2-NSA SEDDS formulation, the ATV free-base solution, and the ATV free-base suspension overlay the data well. In particular, the model predicts the nonlinear increase in exposure seen in the PK data for the ATV-2-NSA SEDDS and ATV free-base solution formulations, and the low, flat exposure for the ATV free-base suspension.
Discussion
A number of technologies are available for increasing the dissolution rate or kinetic solubility of compounds with poor aqueous solubility to increase oral exposure in toxicology studies. However, most of these techniques have limitations in formulating for highdose studies-both in early discovery and in later stages of preclinical and clinical drug development. Lipid-based formulations, in particular, are typically most applicable to highly lipophilic compounds (log P > 5). Because of the desirable features of lipidbased formulations, including ease of preparation, it would be advantageous to extend the applicability of this approach to compounds with lower log P values.
In this study, 2-NSA and Doc lipophilic counterions were used to prepare lipophilic ion-drug pairs to markedly increase solubility in lipid solvents and facilitate development of stable, highconcentration formulations for high-dose studies in discovery. The physical properties of ATV-2-NSA and ATV-Doc are significantly different from those of the free-base form or the common salt forms of ATV. For example, inorganic salt forms of weakly basic drug compounds typically have T m values greater than or equal to that of the free base. This is true for ATV, where bisulfate and chloride salts melt at approximately 213°C and 204°C, respectivelymuch higher than the 2-NSA salt (172°C). ATV-2-NSA's lower T m relative to the T m of the free base, chloride, and bisulfate forms suggests that ATV-2-NSA has a lower crystal lattice energy. The 2-NSA may interfere with the ATV intra-or intermolecular bonding. In addition, the steric hindrance imposed by the bulky naphthalene group of the 2-NSA anion likely results in a crystal structure that is less tightly packed.
The crystalline form of ATV-Doc was not easily isolated, likely due to the flexible nature of the docusate moiety, which hinders short-and long-range ordering of the salt. Nevertheless, consistent with the discussion above for the 2-NSA crystalline form, one would also expect a crystalline Doc salt to have a low T m . The low T m s of the lipophilic salts and their resultant reduced tendency to crystallize increase their solubility in lipid vehicles and enhance emulsion stability, allowing effective formulation at high concentrations to enable high doses.
The two lipophilic salts described here have increased solubility in the SEDDS vehicle. ATV-2-NSA has a 5.7-fold higher solubility than ATV free base in the SEDDS vehicle. The increased lipid solubility of ATV-2-NSA versus ATV free base was evident in the physical stability of supersaturated solutions in SEDDS vehicle prepared by dissolving the respective amorphous forms into the lipid. ATV-2-NSA prepared at 60 mg/mL, or a supersaturation ratio (c/S) of approximately 12.6, did not undergo any crystallization within 30 h, whereas amorphous ATV free base and ATV-Doc both initially dissolved to 60 mg/mL in the SEDDS vehicle, but crystallized to the free base within 0.5 h and 1.5 h, respectively. This conversion to the free base may suggest ATV-Doc undergoes a larger degree of salt dissociation in the vehicle than does ATV-2-NSA.
As discussed in Section 3, the ATV-2-NSA SEDDS emulsion, formed by diluting the SEDDS solution 1:4 in 0.01 N HCl, had better physical stability than either the free-base or ATV-Doc SEDDS formulations (as shown by the data in Table 3 ). In addition, the physical stability of the SEDDS formulation diluted in HCl was better than that of the SEDDS formulation diluted in water. The improved stability of the ATV-2-NSA SEDDS formulation versus the ATV freebase SEDDS formulation in HCl, and the improved stability of ATV-2-NSA SEDDS diluted in HCl versus in water are both likely due to the tendency of the free base to crystallize in an aqueous environment. The use of the ATV-2-NSA salt, particularly in HCl, minimizes the concentration, and therefore the crystallization rate, of the free base. The improved physical stability of the ATV-2-NSA SEDDS emulsion relative to the ATV free-base formulation suggests that the 2-NSA salt form can facilitate oral dosing at higher drug concentrations than the free-base form. Here the increased solubility of the 2-NSA salt allowed effective dosing at six times higher concentrations than the ATV free base. That is, the 2-NSA could be dissolved at 60 mg/mL in the lipid vehicle versus 10 mg/mL for the free base, enabling dosing of the SEDDS formulations at 60 mg/kg for the 2-NSA versus 10 mg/kg for the free base.
Differences in SEDDS solubility and emulsion stability for the ATV-2-NSA, ATV-Doc and ATV free-base formulations did not manifest in exposure differences in vivo at the two lower doses tested (i.e., 10 and 30 mg/kg). Likely, all three formulations sustained dissolved drug concentrations long enough in vivo to allow good absorption of the compound at these lower doses, as evident by the similar AUC values. The exposure for the aqueous suspension of free-base crystals was similar to that of the SEDDS formulations at low dose, suggesting that at these doses, the crystalline solubility is sufficient to provide good absorption. The high permeability of ATV results in rapid absorption to mitigate the limitation of low dissolved drug levels [48] .
At 60 mg/kg, the exposure for the ATV-2-NSA SEDDS formulation was similar to that of the ATV free-base solution, and higher than that of the ATV free-base suspension in SEDDS, suggesting that the ATV-2-NSA SEDDS formulation provided maximum dissolved drug levels in the GI tract to drive absorption. Interanimal variability in exposure was higher for the ATV free-base solution formulation than for the ATV-2-NSA SEDDS formulation, possibly due to precipitation of the solution formulation in vivo. This highlights the fact that even when high drug concentrations in cosolvents can be achieved, the risk of in vivo precipitation, which can lead to a reduced or variable exposure, can be significant. Of course, cosolvent intolerability is another common drawback of such solutions, which can limit their use in early preclinical studies.
The ATV-crystalline aqueous suspension formulation, which is a surrogate for a clinical solid (tablet or capsule) dosage form, gave a 50% lower AUC at 30 mg/kg compared to SEDDS formulations, likely due to lower solubility and dissolution rate of the crystalline form of ATV. Even at 100 mg/kg, no increase in exposure was observed for the crystalline suspension, limiting its utility for toxicology studies.
In this study, ATV exposure increased more than dose proportionally, as the dose increased from 10 to 60 mg/kg in ATV solution and ATV-2-NSA SEDDS formulations (Fig. 7) . For solution formulations, 3-and 6-fold increases in dose resulted in 9-and 20-fold increases in AUC 0-1 , respectively, as the data in Table 4 show. The observed nonlinear PK may have resulted from multiple factors, including saturation of efflux and uptake transporters [45] and enzymatic metabolism [49] . ATV is a known substrate for efflux transporters, such as P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs) [45, 50] . Kis et al. showed that in the presence of a P-gp inhibitor, the ATV efflux ratio was reduced to 1.5 from 11.7 [45] . Moreover, when the ATV concentration was increased substantially (to 100 lM from 1 lM), the efflux ratio was reduced to 1, suggesting a saturable process. ATV is a substrate and moderate inhibitor of CYP3A4 and a competitive inhibitor of UGT1A1 [51] . Therefore, along with efflux saturation, saturation of enzymatic metabolism at higher doses may have also contributed to an increase in exposure that was higher than dose proportional [49] . In silico modeling was done in an attempt to understand the dose-dependent exposure seen in the rat PK studies.
Results from in silico modeling suggests that the absorption of crystalline ATV is solubility-limited. In particular, the model predicts the flat exposure of the aqueous crystalline suspension as a function of dose from 10 to 100 mg/kg. If absorption was primarily limited by dissolution rate, increasing the crystalline surface area by increasing the dose would be expected to increase the exposure across this range. The increased exposure with dose for the SEDDS and solution formulations is therefore likely due to the higher dissolved drug concentrations for these formulations relative to crystalline solubility. The simulations likewise support the hypothesis that metabolism and efflux contribute to the nonlinear PK, as the metabolism and efflux are overcome as dose increases, leading to a superlinear response with dose for the solution and ATV-2-NSA SEDDS formulations.
The increase in exposure with dose is predicted to roll over eventually due to (amorphous) solubility-limited absorption from the ATV-2-SEDDS and ATV free-base solution formulations. Based on the modeling, this roll-off is not expected to occur until above the doses tested in this study. Experimentally, it was shown that the ATV tends to crystallize from the SEDDS formulation before reaching the dose concentrations at which absorption is limited by the amorphous solubility. The present ATV-2-SEDDS formulation precipitates rapidly at the 20 mg/mL dose concentration that would be needed to achieve 100 mg/mL (assuming the typical 5 mg/kg dose volume used here). Because of this, the roll-off in exposure for the current (unoptimized) SEDDS formulation occurs between 12 mg/mL and 20 mg/mL (60 and 100 mg/kg at 5 mL/kg dose volume) due to the limited physical stability of the supersaturated formulations. Increasing the dose volume and/or further optimizing the SEDDS formulation would increase the dose at which the roll-off in exposure occurs. The interpretation of the dose response for various formulations was aided by simulations that demonstrated the impact of metabolism and efflux, particularly at low dose.
The results shown here demonstrate that the use of lipophilic salts can enable high doses and dose concentrations of ATV in lipid formulations. Lipophilic salts can be formed for a variety of weakly acidic or weakly basic drug compounds, typically using a counter ion having a pKa at least several units higher (lower) than the pKa of the corresponding acidic (basic) drug molecule, to ensure robust association. The use of lipophilic salts in lipid vehicles is especially attractive for compounds that have moderate to low lipophilicities and/or compounds with high lipophilicities and high T m . For these compounds, the effective lipophilicity of the compound can be increased, and/or the T m decreased, both of which raise the solubility of the drug compound in lipophilic formulation vehicles, and in the use environment following dispersion and digestion of the vehicle.
Lipophilic salts may find utility in other formulation approaches as well, including in solid amorphous dispersions, in which they can increase the solid state stability by increasing drug solubility in a polymeric dispersion matrix, for example. Based on results here, it is expected that for weakly basic drugs, lipophilic salts incorporated into a liquid lipid-based formulation or into a solid dispersion may limit dissolved drug concentrations in the low pH gastric environment, and therefore the resulting supersaturation and concomitant likelihood of crystallization in the intestine.
Conclusion
We have shown that increasing the lipophilicity of an ionizable compound by preparing a lipophilic salt is a viable approach for increasing its lipid solubility and improving the stability of the associated SEDDS formulation. In this study, lipophilic salts of ATV with 2-NSA and Doc were prepared as model systems for studying the utility of lipophilic salts of weakly basic active compounds with poor aqueous solubility. The physical properties of the two salts-including T g , T m , and solubility-were shown to be significantly different from those of the ATV free base. Most significantly, the solubility of crystalline ATV-2-NSA in a SEDDS formulation was determined to be 5-to 6-fold higher than that of the crystalline free base. The ATV-2-NSA SEDDS formulation also had better physical stability than corresponding SEDDS ATV freebase or ATV-Doc formulations.
The plasma exposure in rats provided by ATV-2-NSA at a given dose was equivalent to that provided by an ATV free-base SEDDS formulation. However, ATV-2-NSA can be dosed at a higher level using this formulation approach, due to its higher solubility in the lipid SEDDS vehicle. Compared to the ATV free-base solution formulation, the ATV-2-NSA salt at high dose had comparable exposure while reducing interanimal variability in exposure.
While these in vivo results are preliminary, with limited animal numbers and an unoptimized vehicle, they suggest this approach shows promise in enabling high-dose testing of low-solubility drug compounds both in early Discovery and in later stages of preclinical and clinical drug development. The comparison of the SEDDS formulation of the ATV-2-NSA lipophilic salt with a suspension of ATV free base in SEDDS or in aqueous vehicles, and with the solution formulation of the free base, shows the potential advantage of using lipophilic salts paired with lipid-based formulations for delivering high doses of low-solubility compounds. In particular, the increased solubility of the lipophilic salt in the lipid vehicle allows higher effective dosing for TK and dose-escalation studies relative to free-base suspensions in either aqueous or lipid vehicles. In addition, lipophilic salts in lipid vehicles provide high dissolved-drug levels that resist precipitation without the use of cosolvents that can lead to uncontrolled precipitation and to adverse effects that interfere with toxicology readouts.
The work described here represents a systematic approach using in vitro, in vivo, and in silico assessment that can be used to guide rational selection of lipophilic-salt SEDDS formulations with resulting utility in the drug-development process. In addition, this study provides a framework for using in vitro, in vivo, and in silico assessment to understand and select formulations for toxicology studies.
